Clinical Trial Update: Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MP-424 with peginterferon alfa-2b and ribavirin in relapser genotype 2 chronic hepatitis C patients; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MP-424
• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-11-03